Ceretas Limited
PublicCeretas Limited is now publicly traded
The data on this page reflects Ceretas Limited's private-market history up to the point it went public, including its funding rounds, valuation, and investors.
Last Round
Grant
Sep 22, 2025
Total Funding Raised
$2.55M
Company Overview
Ceretas Limited has raised $2.55M. It was founded in 2024.
Ceretas Limited is a healthtech company developing a non-invasive, safe, and portable therapeutic ultrasound platform to treat diseases of the brain, such as Alzheimer's disease.
AI Layer
Non-AI
Ceretas Limited Comparables
Compare Ceretas Limited with similar companies based on industry and business-model similarity.
| Company | Similarity | Market Cap |
|---|---|---|
| Grey Matter Neurosciences | 88% | |
| Sound Wave Innovation Co., Ltd. | 84% | |
| Delsona Therapeutics | 82% |
For institutional investors. Book with your work email.
Ceretas Limited Funding Rounds
Historical fundraising activity
| Round | Date | Amount Raised | Valuation | Investors | Sources |
|---|---|---|---|---|---|
| Grant | Sep 22, 2025 | ||||
| Seed | Feb 21, 2025 |
For institutional investors. Book with your work email.
Key People
Founding team and executive leadership
For institutional investors. Book with your work email.
Ceretas Limited Investors
Notable investors and investment history
| Investor | Rounds |
|---|---|
| Sequoia Asset Management | Seed |
| CUREator | Grant |
| Caravel Securities | Seed |
Recent news
Latest coverage and updates
- attends_eventOct 15, 2026
Ceretas Pty Ltd is recognised at the 2026 KCA Awards for Best Spin-Out for commercialising a novel therapeutic ultrasound platform for Alzheimer's disease and other neurodegenerative disorders.
- is_developingSep 16, 2026
Ceretas Pty Ltd is developing the platform, which uses low-intensity focused ultrasound through the skull for potential neuromodulation and blood-brain barrier opening applications.
- is_developingSep 16, 2026
Ceretas Pty Ltd is developing its own image-guided neuronavigation software, with a fully functional prototype delivered and accepted by Brandon BioCatalyst and intended to reduce the required operators from two to one while improving usability and reducing cost of goods.
- receives_financingSep 16, 2026
Ceretas Pty Ltd completes a third CUREator+ Dementia & Cognitive Decline milestone, unlocking an expected $693K final non-dilutive funding tranche in the coming weeks to support its therapeutic ultrasound platform.
For institutional investors. Book with your work email.
Ceretas Limited Filings
Explore SEC and related filing metadata, where available.
| Type | Date | Amount Offered | Amount Sold | Filing | Pages | Download |
|---|
Filing documents are not displayed on this public page. Request access to learn about available coverage.
Book a demoFor institutional investors. Book with your work email.